Sanofi, Mylan Spar Over Surescripts Ruling In EpiPen Fight
Mylan told a Kansas federal judge on Friday that Sanofi is wrong to argue that a recent ruling in the Federal Trade Commission's monopolization case against Surescripts supports allegations that Mylan violated antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article